Algert Global LLC Boosts Holdings in Zoetis Inc. (NYSE:ZTS)

Algert Global LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1,182.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 24,676 shares of the company's stock after purchasing an additional 22,752 shares during the quarter. Algert Global LLC's holdings in Zoetis were worth $4,821,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZTS. Caxton Associates LP acquired a new position in shares of Zoetis during the 1st quarter worth approximately $1,710,000. Silvercrest Asset Management Group LLC boosted its stake in shares of Zoetis by 33.3% during the first quarter. Silvercrest Asset Management Group LLC now owns 12,793 shares of the company's stock valued at $2,165,000 after acquiring an additional 3,193 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in shares of Zoetis during the first quarter valued at $1,658,000. Kennedy Capital Management LLC purchased a new stake in Zoetis during the 1st quarter worth about $883,000. Finally, In Depth Partners LLC raised its stake in Zoetis by 2.8% in the 1st quarter. In Depth Partners LLC now owns 69,688 shares of the company's stock valued at $11,792,000 after purchasing an additional 1,867 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Up 1.0 %

Shares of NYSE ZTS traded up $1.74 during midday trading on Monday, hitting $178.70. The stock had a trading volume of 4,558,329 shares, compared to its average volume of 2,551,175. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a market capitalization of $80.62 billion, a price-to-earnings ratio of 33.49, a PEG ratio of 2.71 and a beta of 0.90. The company has a fifty day moving average price of $185.62 and a 200 day moving average price of $180.72.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. Zoetis's revenue was up 11.6% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis's dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analyst Weigh In

Several research firms have issued reports on ZTS. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a "strong-buy" rating in a research note on Friday, August 9th. Stifel Nicolaus raised their price objective on Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a report on Wednesday, September 18th. Finally, BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research note on Monday, August 12th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.